Evidence map›Paper›PMID 26648817›Full record

ArticleEXCLI journal2015

MicroRNA-15b target Sall4 and diminish in vitro UCB-derived HSCs expansion.

Mahshid Akhavan Rahnama, Ali Akbar Movassaghpour, Masoud Soleimani, Amir Atashi, Azadeh Anbarlou, Karim Shams Asenjan

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Long non-coding RNAs in the regulation of myeloid cells.Journal of hematology & oncology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mahshid Akhavan RahnamaHematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali Akbar MovassaghpourHematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Masoud SoleimaniDepartment of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Amir AtashiDepartment of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Azadeh AnbarlouDepartment of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Karim Shams AsenjanBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tabriz, Iran.
Tarbiat Modares University · IRHigh Institute for Education and Research in Transfusion Medicine · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic Stem Cells (HSCs) are cells that have the ability to self-renewal and differentiate into all of hematopoietic lineages. The lack of donors and unavailable efficient protocols for ex vivo expansion of HSCs, are obstacles in successful cell therapies. MicroRNAs (also refer as miRNAs or miRs) have significant roles in hematopoiesis; they can effect on HSCs expansion, maintaining undifferentiated state, self-renewal and differentiation. Recently attentions have been given to these small regulatory molecules to utilize them in order to expand HSCs. Using bioinformatics analysis we identified Sall4 as putative target of miR-15b and miR-219-5p. Relative expression levels of miRNAs and Sall4 were evaluated by qRT-PCR. Here we show 247-fold and 4.2-fold increasing Sall4 expression level compared to control group in CD34(+) cells nucleofected by anti-miR-15b and anti-miR-219-5p, respectively. These data showed that anti-miR-15b can promote clonogenic capacity of HSCs and also we found that miR-15b alone was able to increase the number of CD34(+)HSCs in vitro by more than 2 fold by targeting Sall4. Moreover, level of CD34 marker in HSCs nucleofected by anti-miR-15b increased more than 50 %. Our analysis showed no statistically difference in mRNA level of Sall4 after nucleofection of anti-miR-219-5p. Sall4 is a factor capable of enhancing HSC expansion significantly. We demonstrated that inhibition of miR-15b can enhance ex vivo expansion of UCB-derived HSCs and also expression of Sall4 allowed expansion and preserve self- renewal of CD34(+) HSCs.

Indexed as

expansionHSCsmiR-15bmiR-219-5pSall4

Identifiers

PMID26648817
PMCPMC4669904
OpenAlexW2223564785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.